Decitabine salvage for <i>TP53</i>-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy-Reference-Cited by-同舟云学术

Decitabine salvage for <i>TP53</i>-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy

Published:2022-03-03 Issue:7 Volume:107 Page:1709-1713
ISSN:1592-8721
Container-title:Haematologica
language:
Short-container-title:haematol

Author:

Ferraro Francesca,Gruszczynska Agata,Ruzinova Marianna B.,Miller Christopher A.,Percival Mary Elizabeth,Uy Geoffrey L.,Pusic Iskra,Jacoby Meagan A.,Christopher Mathew J.,Kim Miriam Y.,Westervelt Peter,Cashen Amanda F.,Schroeder Mark A.,DiPersio John F.,Abboud Camille N.,Wartman Lukas D.,Gao Feng,Link Daniel C.,Ley Timothy J.,Welch John S.

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Reference15 articles.

1. Rucker FG, Schlenk RF, Bullinger L. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012; 119(9):2114-2121.

2. Maiti A, Qiao W, Sasaki K. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021; 96(3):282-291.

3. Papaemmanuil E, Gerstung M, Bullinger L. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374(23):2209-2221.

4. Stengel A, Kern W, Haferlach T. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017; 31(3):705-711.

5. Dohner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients;Leukemia Research;2024-10

2. Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes;Blood Advances;2023-08-10

3. TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA;Mediterranean Journal of Hematology and Infectious Diseases;2023-06-29

4. TP53 signal pathway confers potential therapy target in acute myeloid leukemia;European Journal of Haematology;2023-02-07